Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satraplatin Expanded Access in HRPC (SPERA)
NCT00450970Phase 3Terminated
- Sponsor
- Agennix AG
- Start
- Feb 2007
- Primary completion
- Mar 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of satraplatin in prostate cancer (PCa), sponsored by Agennix AG. Started Feb 2007; status: terminated.
02
Drugs
satraplatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00450970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450970.